Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% from the current price [5][9]. Core Insights - The company is expected to achieve a net profit of between RMB 270 million and RMB 320 million in 2025, representing a year-on-year increase of 55% to 84%. The fourth quarter of 2025 is projected to show a turnaround with a net profit of RMB 20 million to RMB 70 million [5]. - The company has implemented significant reforms, leading to improved operational efficiency and a reduction in sales expense ratio by over 30% year-on-year. This has resulted in a marginal improvement in business operations [8]. - For 2026, the company anticipates continued operational improvements, with stable growth in its raw materials business and a positive trend in its medical terminal products, which saw a 14.5% year-on-year revenue increase in Q3 2025 [8]. Financial Summary - The company forecasts net profits of RMB 310 million, RMB 530 million, and RMB 600 million for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 76.4%, 72%, and 13.3% [8]. - Earnings per share (EPS) are projected to be RMB 0.64, RMB 1.10, and RMB 1.24 for the same years, with corresponding price-to-earnings (P/E) ratios of 70, 41, and 36 [8]. - The company's revenue is expected to be RMB 4.895 billion in 2025, with a gradual increase to RMB 5.980 billion by 2027 [11].

Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% from the current price [5][9]. Core Insights - The company is expected to achieve a net profit of between RMB 270 million and RMB 320 million in 2025, representing a year-on-year increase of 55% to 84%. The fourth quarter of 2025 is projected to show a turnaround with a net profit of RMB 20 million to RMB 70 million [5]. - The company has implemented significant reforms, leading to improved operational efficiency and a reduction in sales expense ratio by over 30% year-on-year. This has resulted in a marginal improvement in business operations [8]. - For 2026, the company anticipates continued operational improvements, with stable growth in its raw materials business and a positive trend in its medical terminal products, which saw a 14.5% year-on-year revenue increase in Q3 2025 [8]. Financial Summary - The company forecasts net profits of RMB 310 million, RMB 530 million, and RMB 600 million for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 76.4%, 72%, and 13.3% [8]. - Earnings per share (EPS) are projected to be RMB 0.64, RMB 1.10, and RMB 1.24 for the same years, with corresponding price-to-earnings (P/E) ratios of 70, 41, and 36 [8]. - The company's revenue is expected to decline to RMB 4.895 billion in 2025 before recovering to RMB 5.315 billion in 2026 and RMB 5.980 billion in 2027 [11].

Group 1 - The core viewpoint is that AI is accelerating the transformation of the healthcare industry, with significant growth potential in companies like Huaxi Biological, which expects a net profit increase of 54.93%-83.63% by 2025 [1] - Huaxi Biological's stock led the gains in the Sci-Tech Innovation Board, rising by 7.70%, indicating strong market interest and confidence in its future performance [1] - The Sci-Tech 100 ETF has shown significant liquidity and growth, with a recent trading volume of 1.74 billion yuan and a 1.32 billion yuan increase in scale over the past two weeks [1] Group 2 - According to Everbright Securities, AI has become a core productivity driver in the new infrastructure of healthcare, with AI drug development and AI medical imaging being the most mature sectors [2] - The future competition in the AI healthcare space will focus on exclusive high-quality private data and the ability to create closed-loop business scenarios [2] - The Sci-Tech 100 ETF closely tracks the Sci-Tech 100 Index, which focuses on high-growth sectors including semiconductors, pharmaceuticals, and new energy [2]

Core Viewpoint - Huaxi Biological announced an expected net profit of 270 million to 320 million yuan for 2025, representing a year-on-year growth of 54.93% to 83.63% [1] - The growth is attributed to a systematic transformation rather than short-term scale expansion, focusing on "agile management, growth, and efficiency" [1][3] Financial Performance - The net profit excluding non-recurring gains is projected to be between 167 million and 217 million yuan, with a year-on-year increase of 55.68% to 102.29% [1] - Management expenses are expected to decrease by over 10% year-on-year in 2025 [1] Operational Strategy - The company emphasizes professional development and optimizes its business structure and resource allocation, leading to a sales expense reduction of over 30% [2] - Cost and expense management has been refined to support profit growth [2] Innovation and Digital Transformation - Huaxi Biological focuses on scientific research as its core competitive advantage, particularly in glycoscience and cell biology [2] - The company is enhancing its industrialization capabilities in bioactive substances and regenerative materials through a synthetic biology research and development system [2] - Continuous digital transformation is improving operational efficiency across all business scenarios, including AI integration in various functions [2] Long-term Development - The 2025 performance growth reflects the company's commitment to high-quality development and core capability building [3] - The company aims to maintain its competitive advantage through technological innovation and a comprehensive industrial layout [3]

Group 1 - The core viewpoint of the article is that Huaxi Biological Technology Co., Ltd. expects significant growth in net profit for the year 2025, reflecting the initial success of its strategic shift towards "quality growth" [1] - The company anticipates a net profit attributable to shareholders of between 270 million to 320 million yuan for 2025, representing an increase of approximately 54.93% to 83.63% compared to the previous year's profit of 174 million yuan [1] - The net profit excluding non-recurring gains and losses is expected to be between 167 million to 217 million yuan, with a year-on-year growth rate of 55.68% to 102.29%, indicating a strong growth momentum [1] Group 2 - The significant increase in performance is attributed to the company's commitment to the core strategy of "agile management and growth efficiency," which promotes a transition from scale expansion to quality growth [1] - The company has optimized its organizational structure and strengthened functional collaboration, leading to a notable improvement in operational efficiency, with management expenses decreasing by over 10% year-on-year [1] - Sales expenses have also seen a reduction of over 30% year-on-year due to optimized business structure and resource allocation, which has solidified the profit foundation through strict cost control [1] Group 3 - In terms of research and technological innovation, the company is focusing on two fundamental disciplines: glycoscience and cell biology, enhancing systematic research on extracellular matrix regulation, aging intervention, and tissue regeneration [2] - The company is leveraging its synthetic biology research and development system and pilot transformation platform to improve the industrialization capabilities of bioactive substances and regenerative materials, accelerating the conversion of research results into products and solutions [2] - The company is also advancing its original technology layout and product transformation in key areas such as aging intervention, tissue regeneration, and functional materials, thereby solidifying its technological foundation for medium to long-term business development [2] Group 4 - The company plans to continuously integrate artificial intelligence technology across its entire business chain to drive long-term improvements in operational quality through technology [3]

行 业 及 产 业 美容护理 2026 年 02 月 01 日 行 业 研 究 / 行 业 点 评 相关研究 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 A0230511040052 wanglp@swsresearch.com 业绩预告彰显板块景气度，建议关注节前促销 看好 ——化妆品医美行业周报 20260201 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 证 券 研 究 报 告 - ⚫ 本阶段化妆品医美板块表现弱于市场。2026 年 1 月 23 日至 2026 年 1 月 30 日期间， 申万美容护理指数下滑 3.8%，表现弱于市场。其中，申万化妆品指数下滑 3.6%，弱于 申万 A 指 1.9pct；申万个护用品指数下滑 4.6%，弱于申万 A 指数 3.0pct。 ⚫ 周观点：业绩预告彰显板块景气度 ...

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial application, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor of NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4][6]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse reactions [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, making NMN supplements, which can provide up to 300 times the dietary intake, more effective for achieving beneficial doses [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][12]. - Leading companies are innovating in full enzymatic synthesis and patenting technologies to create competitive advantages [12]. Market Trends and Demand - The aging population and increasing anti-aging awareness among younger demographics are driving demand for NMN products, with the market expected to grow significantly [19][21]. - The NMN market in China is projected to exceed 3 billion yuan by 2025, with applications expanding beyond health supplements and cosmetics into areas like pet nutrition and agricultural technology [28][24]. Application Areas - NMN is primarily used in health supplements (90% market share) and cosmetics (10-20% market share), with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. - The Chinese health supplement market is expected to surpass 430 billion yuan by 2025, indicating substantial growth potential for NMN products [40]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60-70% of market share [35]. Regulatory Environment - The regulatory landscape for NMN is evolving, with significant progress in China towards legalizing NMN as a health supplement, which could reshape the market dynamics [17][61]. - The "blue hat" certification for health supplements in China represents the highest standard for product safety and compliance, which could significantly impact market structure if achieved [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating a focus on compliance and innovation to unlock market potential [61][63]. - Companies are encouraged to innovate their business models and extend their value chains to enhance competitiveness and market presence [66].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经华熙生物科技股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现归属 于母公司所有者的净利润人民币27,000.00万元到32,000.00万元，与上年同期（法定披露数据）相比，将 增加9,573.26万元到14,573.26万元，同比增加54.93%到83.63%。 （2）预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润16,700.00万元到21,700.00 万元，与上年同期（法定披露数据）相比，将增加5,972.80万元到10,972.80万元，同比增加55.68%到 102.29%。 二、上年同期业绩情况和财务状况 （一）利润总额：21,339.29万元。归属于母公司所有者的净利润：17,426.74万元。归属于母公司所有者 的扣除非经常性损益的净利润：10,727.20万元。 组织层面，公司整合职能重叠部门，优化 ...

Group 1 - Guangdong Mingzhu expects a net profit increase of 2908.49%-3577.04% year-on-year for 2025 [1] - Sainuo Medical anticipates a net profit growth of 2767%-3233% year-on-year for 2025 [1] - Lingdian Electric Control forecasts a net profit rise of 640.16%-804.64% year-on-year for 2025 [1] - Bojie Co. predicts a net profit increase of 484.16%-618.97% year-on-year for 2025 [1] - Kexing Pharmaceutical expects a net profit growth of 328.83%-455.89% year-on-year for 2025 [1] - Xiangcai Co. anticipates a net profit increase of 266.41%-403.81% year-on-year for 2025 [1] - Xinyi Sheng forecasts a net profit rise of 231.24%-248.86% year-on-year for 2025 [1] - Tongzhou Electronics predicts a net profit increase of 151.40%-230.42% year-on-year for 2025 [1] - Zhaofeng Co. expects a net profit growth of 136.26%-164.89% year-on-year for 2025 [1] - Kaige Precision Machinery anticipates a net profit increase of 133.99%-193.55% year-on-year for 2025 [1] - Sankeshu forecasts a net profit rise of 128.96%-189.21% year-on-year for 2025 [1] - Huazi Industrial expects a net profit growth of 128.00%-167.00% year-on-year for 2025 [1] - Zhite New Materials anticipates a net profit increase of 117.11%-171.39% year-on-year for 2025 [1] - Ecovacs expects a net profit growth of 110.90%-123.30% year-on-year for 2025 [1] - Jingquan Hua forecasts a net profit increase of 109.32%-140.72% year-on-year for 2025 [1] - Guoxuan High-Tech anticipates a net profit rise of 107.16%-148.59% year-on-year for 2025 [1] - Changjiang Securities expects a net profit growth of 101.37% year-on-year for 2025 [1] - Shanwaishan forecasts a net profit increase of 98%-125% year-on-year for 2025 [1] - Zhongji Xuchuang anticipates a net profit rise of 89.50%-128.17% year-on-year for 2025 [1] - Huachuang Yuxin expects a net profit growth of 86%-175% year-on-year for 2025 [1] - Kori Technology forecasts a net profit increase of 68.61%-115.25% year-on-year for 2025 [1] - Western Gold anticipates a net profit rise of 67.58%-93.21% year-on-year for 2025 [1] - Shandong Gold expects a net profit growth of 56%-66% year-on-year for 2025 [1] - Huaxi Biological anticipates a net profit increase of 54.93%-83.63% year-on-year for 2025 [1] - Nairui Radar expects a net profit growth of approximately 54.16% year-on-year for 2025 [1] - Lingyun Optical anticipates a net profit rise of approximately 50.75% year-on-year for 2025 [1] - Zhongjin Company expects a net profit increase of 50%-85% year-on-year for 2025 [1] - Dongwu Securities forecasts a net profit growth of 45%-55% year-on-year for 2025 [1] - Longping High-Tech anticipates a net profit increase of 14.17%-66.86% year-on-year for 2025 [1] Group 2 - Jiangfeng Electronics expects a net profit increase of 7.5%-27.5% year-on-year for 2025 [2]

Core Insights - The article discusses recent advancements in the medical field, particularly focusing on new cholesterol-lowering drugs and metabolic drugs like tirzepatide, which are being researched for cardiovascular outcomes [1] - There is a notable trend in the industry towards the use of AI in drug development, gene editing, and synthetic biology, which is expected to enhance efficiency from research and development to production [1] - Chinese companies, including Huaxi Biological, are actively investing in synthetic biology and biomanufacturing to improve the scalability and accessibility of certain bioactive components [1] Group 1 - Recent approvals of new cholesterol-lowering drugs and ongoing research into metabolic drugs are significant developments in the healthcare sector [1] - AI-assisted technologies are accelerating the efficiency of drug development and production, potentially lowering costs and increasing accessibility [1] - The need for more clinical evidence and long-term follow-up to validate the safety and effectiveness of these new technologies remains a critical consideration [1] Group 2 - Companies like Huaxi Biological are focusing on synthetic biology and biomanufacturing to enhance the production of bioactive components [1] - There is an emphasis on early risk identification and management of lifestyle and chronic disease indicators as practical health strategies for the general public [1]